Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Date:3/11/2009

ed.com/" target="_new">www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that closing conditions under our agreement with Merck & Co., Inc. may not be met, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for MMD may not actually match up with our external assessment, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this r
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Research and Markets  has announced the addition of the ... report to their offering. This report analyzes ... Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided for ...
(Date:8/19/2014)... Research and Markets  has announced the addition ... Strategic Business Report" report to their offering. ... Fuel Cells (SOFCs) in US$ Thousands. The report provides separate ... Europe , Asia-Pacific , ... for the period 2012 through 2020. Market data and analytics ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
(Date:8/19/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... novel C. difficile development program will ... Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September ... Synthetic Biologics, Senior Vice President, Research ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... March 11 earthquake and rolling blackouts that are severely ... internship program NanoJapan is scrambling to run its annual ... travel to Japan for lab internships, NanoJapan is offering ... students to Rice University laboratories for three months. ...
... 25, 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), a ... announced it has entered into definitive agreements with ... Partners, LLC, Deerfield Management and Merlin Nexus, and ... a $30.4 million private placement financing of equity ...
... Texas, May 25, 2011 /PRNewswire/ -- ... company, today announced that the United States Patent and Trademark ... patent entitled "Saposin D and Fam3C are Biomarkers for Alzheimer,s ... Fam3c as well as combinations that include these biomarkers. ...
Cached Biology Technology:Reverse NanoJapan: Rice to host 25-30 Japanese students 2WaferGen Announces $30 Million Financing 2WaferGen Announces $30 Million Financing 3WaferGen Announces $30 Million Financing 4Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3
(Date:8/19/2014)... in supermarkets to encourage healthier spending habits? A new ... very question by tracking the purchasing records in a ... rate the nutritional value of foods for sale. , ... Just, PhD, and Brian Wansink PhD, author of Slim ... 150 Hannaford Supermarkets in the Northeastern United States between ...
(Date:8/19/2014)... at retail seafood counters in 10 different states ... consumers to unexpectedly high levels of mercury, a ... a fish of the same species, but from ... offense, according to new research by University of ... seafood is essential to allow consumers to choose ...
(Date:8/19/2014)... seas during warm phases and became extinct during cold ... a link between marine crocodilian diversity and the evolution ... 140 million years. , The research, led by ... and formerly from the University of Bristol, UK is ... crocodiles are ,cold-blooded, animals that mainly live in fresh ...
Breaking Biology News(10 mins):Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Evolution of marine crocodilians constrained by ocean temperatures 2
... methods and better testing systems are needed to advance ... to a series of review articles in Human ... Ann Liebert, Inc ( www.liebertpub.com ). The articles and ... www.liebertpub.com/hum Prostate cancer is one of the ...
... Oxford, 12 July 2010 - The British Mycological Society, ... technical and medical information, today announced the final programme ... Fungi. This congress takes place every 4 years at ... the Edinburgh International Conference Centre, a comprehensive programme encompasses ...
... with your chip shot? Constant drills with your wedge may ... a new study shows why. Previous studies have shown ... better than practice focused on a single task. Cognitive neuroscientists ... paradox in a new study in Nature Neuroscience . ...
Cached Biology News:Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy 2The biology of fungi -- 1.5 million species -- 1 congress 2Why (smart) practice makes perfect 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
QML offers standard and customized paraffin embedded tissue blocks....
Request Info...
Biology Products: